Update shared on 16 Dec 2025
Agfa-Gevaert: Time to Care, Time to Act
- Agfa-Gevaert is no longer a company to diagnose but a patient needing immediate intervention, with time as its scarcest resource.
- Years of structural pressure, shrinking markets, and repeated cost measures make delay only more costly.
- Recent board changes mark a shift from strategy to execution, prioritizing financial discipline and decisive action over sustaining unsustainable structures.
- Painful though it is, acting now is justified to preserve what remains viable.
For management, shareholders, policymakers, and increasingly unions, the message is painfully clear:
It simply has to be done.
Recent publicly reported developments illustrate the pressures described:
- Er verdwijnen nu al 470 jobs bij Agfa-Gevaert, en zelfs dat is niet genoeg: “Er volgen nog besparingen in Mortsel”
- Agfa-Gevaert NV Announces Board and Committee Changes, Effective 11 December 2025
- Agfa Gevaert: Paul Owsianowski joins Board of Directors Agfa-Gevaert NV
- Nog eens 145 banen bedreigd bij Agfa in Mortsel en Heultje: "Vraag naar medische film in China daalt versneld"
"This is not financial advice. All views expressed are personal interpretations of publicly available information and are not predictions or recommendations."
Have other thoughts on Agfa-Gevaert?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
The user RecMag has a position in ENXTBR:AGFB. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.